RU2185824C2 - Применение топирамата или его производных для получения лекарственного средства для лечения маниакально-депрессивных биполярных расстройств - Google Patents

Применение топирамата или его производных для получения лекарственного средства для лечения маниакально-депрессивных биполярных расстройств Download PDF

Info

Publication number
RU2185824C2
RU2185824C2 RU98123607/14A RU98123607A RU2185824C2 RU 2185824 C2 RU2185824 C2 RU 2185824C2 RU 98123607/14 A RU98123607/14 A RU 98123607/14A RU 98123607 A RU98123607 A RU 98123607A RU 2185824 C2 RU2185824 C2 RU 2185824C2
Authority
RU
Russia
Prior art keywords
formula
topiramate
derivatives
alkyl
compounds
Prior art date
Application number
RU98123607/14A
Other languages
English (en)
Russian (ru)
Other versions
RU98123607A (ru
Inventor
Ричард П. Шэнк
Original Assignee
Орто-Макнейл Фармасьютикал, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Орто-Макнейл Фармасьютикал, Инк. filed Critical Орто-Макнейл Фармасьютикал, Инк.
Publication of RU98123607A publication Critical patent/RU98123607A/ru
Application granted granted Critical
Publication of RU2185824C2 publication Critical patent/RU2185824C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
    • H04N21/00—Selective content distribution, e.g. interactive television or video on demand [VOD]
    • H04N21/40—Client devices specifically adapted for the reception of or interaction with content, e.g. set-top-box [STB]; Operations thereof
    • H04N21/43—Processing of content or additional data, e.g. demultiplexing additional data from a digital video stream; Elementary client operations, e.g. monitoring of home network or synchronising decoder's clock; Client middleware
    • H04N21/442—Monitoring of processes or resources, e.g. detecting the failure of a recording device, monitoring the downstream bandwidth, the number of times a movie has been viewed, the storage space available from the internal hard disk
    • H04N21/44213—Monitoring of end-user related data
    • H04N21/44222—Analytics of user selections, e.g. selection of programmes or purchase activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Social Psychology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Databases & Information Systems (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Multimedia (AREA)
  • Signal Processing (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
RU98123607/14A 1996-06-28 1997-06-24 Применение топирамата или его производных для получения лекарственного средства для лечения маниакально-депрессивных биполярных расстройств RU2185824C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2085096P 1996-06-28 1996-06-28
US60/020,580 1996-06-28
US08/881,008 US5753693A (en) 1996-06-28 1997-06-23 Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder

Publications (2)

Publication Number Publication Date
RU98123607A RU98123607A (ru) 2000-09-27
RU2185824C2 true RU2185824C2 (ru) 2002-07-27

Family

ID=26693960

Family Applications (1)

Application Number Title Priority Date Filing Date
RU98123607/14A RU2185824C2 (ru) 1996-06-28 1997-06-24 Применение топирамата или его производных для получения лекарственного средства для лечения маниакально-депрессивных биполярных расстройств

Country Status (21)

Country Link
US (1) US5753693A (enExample)
EP (1) EP0932398B1 (enExample)
JP (1) JP2002515875A (enExample)
KR (1) KR20000022233A (enExample)
CN (1) CN1224350A (enExample)
AP (1) AP1401A (enExample)
AT (1) ATE330593T1 (enExample)
AU (1) AU739363B2 (enExample)
BR (1) BR9712783A (enExample)
CA (1) CA2258895C (enExample)
CZ (1) CZ297342B6 (enExample)
DE (1) DE69736183T2 (enExample)
ES (1) ES2267144T3 (enExample)
HU (1) HUP0003381A3 (enExample)
IL (1) IL127714A (enExample)
NO (1) NO317641B1 (enExample)
NZ (1) NZ333565A (enExample)
RU (1) RU2185824C2 (enExample)
SK (1) SK180498A3 (enExample)
WO (1) WO1998000123A1 (enExample)
ZA (1) ZA975773B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2317301C2 (ru) * 2002-10-31 2008-02-20 Орто-Макнейл Фармасьютикал, Инк. Непрерывный способ получения сульфаматных производных фруктопиранозы
RU2330041C2 (ru) * 2003-01-03 2008-07-27 Орто-Макнейл Фармасьютикал, Инк. Новые соли противосудорожных соединений

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE261724T1 (de) 1998-11-17 2004-04-15 Ortho Mcneil Pharm Inc Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
AU1909700A (en) * 1998-12-03 2000-06-19 Ortho-Mcneil Pharmaceutical, Inc. Topiramate and related derivatives for treating Schizophrenia
US6552000B2 (en) 1999-02-08 2003-04-22 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating autism
NZ513643A (en) 1999-02-24 2005-04-29 Univ Cincinnati Use of sulfamate derivatives for treating impulse control disorders
US6583172B1 (en) 1999-04-08 2003-06-24 Richard P. Shank Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders
US6420369B1 (en) 1999-05-24 2002-07-16 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating dementia
US7553818B2 (en) * 1999-06-14 2009-06-30 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20080255093A1 (en) * 1999-06-14 2008-10-16 Tam Peter Y Compositions and methods for treating obesity and related disorders
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
WO2000076493A1 (en) 1999-06-14 2000-12-21 Thomas Najarian Combination therapy for effecting weight loss and treating obesity
US7659256B2 (en) * 1999-06-14 2010-02-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7674776B2 (en) 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7056890B2 (en) 1999-06-14 2006-06-06 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US6191117B1 (en) * 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity
CA2417304A1 (en) * 2000-08-02 2002-02-07 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful for the treatment of depression
AU2002227052A1 (en) 2000-11-30 2002-06-11 University Of Florida Treatments for neurogenetic disorders, impulse control disorders, and wound healing
CA2459146A1 (en) * 2001-08-30 2003-03-13 Ortho-Mcneil Pharmaceutical, Inc. Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors
US20040235957A1 (en) * 2001-10-12 2004-11-25 David Bleakman Use of sulfonamide derivatives as pharmaceuticals compounds
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US6559293B1 (en) 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
US20090088443A1 (en) * 2002-02-15 2009-04-02 Julius Remenar Novel crystalline forms of conazoles and methods of making and using the same
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
IL163846A0 (en) * 2002-03-01 2005-12-18 Univ South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
IL165383A0 (en) * 2002-06-21 2006-01-15 Transform Pharmaceuticals Inc Pharmaceutical compositions with improved dissolution
EP1534238A1 (en) * 2002-07-29 2005-06-01 ALZA Corporation Formulations and dosage forms for controlled delivery of topiramate
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US20050070524A1 (en) * 2003-06-06 2005-03-31 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders
WO2005065648A2 (en) * 2003-12-29 2005-07-21 Alza Corporation, Inc., Novel drug compositions and dosage forms of topiramate
AR049646A1 (es) * 2004-06-16 2006-08-23 Janssen Pharmaceutica Nv Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
JP4912312B2 (ja) * 2004-08-24 2012-04-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗痙攣薬として有用な新規なベンゾ−縮合ヘテロアリールスルファミド誘導体
CA2609185A1 (en) * 2005-05-20 2006-11-30 Ahmed F. Abdel-Magid Process for preparation of sulfamide derivatives
US8937096B2 (en) * 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8716231B2 (en) * 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8691867B2 (en) * 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8497298B2 (en) * 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8492431B2 (en) * 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US20070191450A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Mania and Bipolar Disorder
US20070191449A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
AU2007253814A1 (en) * 2006-05-19 2007-11-29 Janssen Pharmaceutica N.V. Co-therapy for the treatment of epilepsy
WO2008027557A2 (en) * 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
EP2394643B1 (en) 2006-11-17 2015-09-02 Supernus Pharmaceuticals, Inc. Sustained-release formulations of topiramate
EP2363113B1 (en) 2006-12-04 2017-08-02 Supernus Pharmaceuticals, Inc. Enhanced immediate release formulations of topiramate
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US8580298B2 (en) * 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
US20090304789A1 (en) * 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
WO2010008776A2 (en) 2008-06-23 2010-01-21 Janssen Pharmaceutica Nv Disposable patch and reusable sensor assembly for use in medical device localization and mapping systems
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
WO2020104837A1 (en) 2018-11-21 2020-05-28 Rosemont Pharmaceuticals Limited Oral topiramate suspension formulations with extended shelf stability and enhanced bioavailability

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2050852C1 (ru) * 1992-06-05 1995-12-27 Замощина Татьяна Алексеевна Способ пролонгирования биологической активности солей лития

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US5384327A (en) * 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2050852C1 (ru) * 1992-06-05 1995-12-27 Замощина Татьяна Алексеевна Способ пролонгирования биологической активности солей лития

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
АВРУЦКИЙ Г.Я., НЕДУВА А.А. Лечение маниакально-депрессивного психоза. В кн.: Лечение психически больных. - М.: Медицина , 1988, с.292-308. *
КОРКИНА М.В. и др. Маниакально-депрессивный психоз. В кн.: Психиатрия. - М.: Медицина, 1995, с.416-420. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2317301C2 (ru) * 2002-10-31 2008-02-20 Орто-Макнейл Фармасьютикал, Инк. Непрерывный способ получения сульфаматных производных фруктопиранозы
RU2330041C2 (ru) * 2003-01-03 2008-07-27 Орто-Макнейл Фармасьютикал, Инк. Новые соли противосудорожных соединений

Also Published As

Publication number Publication date
SK180498A3 (en) 2000-03-13
NO986051D0 (no) 1998-12-22
ATE330593T1 (de) 2006-07-15
NO986051L (no) 1999-02-23
IL127714A0 (en) 1999-10-28
JP2002515875A (ja) 2002-05-28
AU739363B2 (en) 2001-10-11
WO1998000123A1 (en) 1998-01-08
AP9801427A0 (en) 1998-12-31
DE69736183T2 (de) 2007-04-26
NZ333565A (en) 2000-07-28
AP1401A (en) 2005-04-29
CA2258895A1 (en) 1998-01-08
ES2267144T3 (es) 2007-03-01
IL127714A (en) 2004-08-31
EP0932398A1 (en) 1999-08-04
CN1224350A (zh) 1999-07-28
DE69736183D1 (de) 2006-08-03
KR20000022233A (ko) 2000-04-25
US5753693A (en) 1998-05-19
BR9712783A (pt) 2000-10-24
EP0932398B1 (en) 2006-06-21
CZ297342B6 (cs) 2006-11-15
HUP0003381A3 (en) 2001-12-28
NO317641B1 (no) 2004-11-29
HUP0003381A2 (hu) 2001-05-28
CA2258895C (en) 2006-06-06
AU3409697A (en) 1998-01-21
CZ427798A3 (cs) 1999-08-11
ZA975773B (en) 1998-12-28

Similar Documents

Publication Publication Date Title
RU2214241C2 (ru) Способ лечения ожирения и способ индуцирования потери веса у млекопитающих
AU739363B2 (en) Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of manic-depressive bipolar disorders
AU774282B2 (en) Anticonvulsant derivatives useful in reducing blood glucose levels
US5760007A (en) Anticonvulsant derivatives useful in treating neuropathic pain
US5935933A (en) Anticonvulsant derivatives useful in treating neuropathic pain
JP4825353B2 (ja) 血圧を下げることに有用な抗痙攣薬誘導体
CA2369093C (en) Anticonvulsant derivatives useful in lowering lipids
US20020052325A1 (en) Anticonvulsant derivatives useful in maintaining weight loss
EP0932400B1 (en) Anticonvulsant derivatives useful in treating neuropathic pain
EP1143917B1 (en) Anticonvulsant derivatives useful in treating post traumatic stress disorder
KR100496932B1 (ko) 비만치료에유용한항경련성설파메이트유도체
JP4709392B2 (ja) 血液グルコースレベルを下げることに有用な抗痙攣薬誘導体
HK1018743B (en) Anticonvulsant sulfamate derivatives useful in treating obesity

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20070625